Laurie Barclay, MD Aug. 23, 2002
Glutathione may protect against the neurotoxicity of oxaliplatin, a relatively new chemotherapeutic used in the treatment of colorectal and other cancers, according to the results of a randomized controlled trial reported in the Aug. 15 issue of the Journal of Clinical Oncology. Even better, this inexpensive drug does not adversely affect the efficacy of oxaliplatin.
“An optimal strategy for reducing the neurotoxicity associated with oxaliplatin may be the use of agents such as glutathione, which may be able to prevent the initial accumulation of platinum adducts in dorsal root ganglia,” write Stefano Cascinu, MD, and colleagues from the Universitaria di Parma in Italy. “The lack of toxicity and interference with oxaliplatin activity, as well as its low economic cost, makes glutathione an ideal new drug for the prevention of oxaliplatin-induced neuropathy in colorectal cancer patients.” In this double-
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!